Genmab — November 2020
-
DnB Markets
Genmab - First proprietary pipeline kill
Today Genmab announced that it will not advance the development of enapotamab vedotin (EV), citing that the data did not meet its stringent criteria for proof-of-concept. This confirms the company’s strategy to end projects that are not efficacious enough and we believe it will be likely to also scrap DR5/DR5. Genmab’s focus is on progressing already-partnered projects. We reiterate our HOLD but have cut our target price o DKK2,320 (2,352) -
UBS also cut with DKK 50, from 2680 to 2630. Buy rating stays
-
Citi stays at 3000, keeps buy rating, says top sales for axl was usd 60m
-
Citi efter Genmab dropper kræftmiddel: Overreaktion https://borsen.dk/nyheder/virksomheder/citi-efter-genmab-dropper-kraeftmiddel-overreaktion-det-var-jo-allerede-paa-vej-i-graven
-
Citi Dkk 20 per aktie
-
142,1???
-
Vi skal da over et år tilbage for at finde det niveau
-
Mit estimat er usd 241,6m
-
-
Correct Dara US sales for October is 237,5M USD
-
Darzalex salg for oktober var USD 237,5M. En stigning på 1,2% i forhold til sidste måned. Faspro udgør ca. 40% af salget
-
Warren Buffett bets Big on pharma space. https://www.moneycontrol.com/news/business/markets/warren-buffett-is-bullish-on-stocks-again-bets-big-on-pharma-space-6149551.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind